Patent classifications
C12N2501/113
Treatment of opioid addiction using fibroblasts and products thereof
Disclosed are methods and compositions comprising fibroblasts and/or products derived thereof for the inhibition and/or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and/or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.
EX VIVO PROLIFERATION OF EPITHELIAL CELLS
The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
Organoid and method for producing same
The present invention provides a method for producing a heart organoid and/or a lung organoid, comprising the step of: culturing an embryoid body in the presence of an FGF protein on a surface of a gel containing an extracellular matrix constituent protein.
GENERATION OF NEURAL STEM CELLS FROM UNDIFFERENTIATED HUMAN EMBRYONIC STEM CELLS
The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
METHODS OF TREATING ISCHEMIC SPASTICITY
The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.
Ex vivo proliferation of epithelial cells
The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
METHODS FOR GENREATING THE INNER EAR AND OTHER CRANIAL PLACODE-DERIVED TISSUES USING PLURIPOTENT STEM CELLS
Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGF, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.
TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF
Disclosed are methods and compositions comprising fibroblasts and/or products derived thereof for the inhibition and/or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and/or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.
Erythroid production
This invention provides method and media suitable for inducing and supporting the differentiation of stem cells into erythroid cells.
Method for undifferentiated growth of mesenchymal stem cell and method for concentration of mesenchymal stem cell
A method in accordance with the present invention includes the steps of: concentrating cord blood-derived mesenchymal stem cells; and causing the mesenchymal stem cells thus concentrated to grow with use of a particular factor while maintaining undifferentiated state of the mesenchymal stem cells.